

# Robust Pipeline of Switch-Control Kinase Inhibitors

		PRE-CLINICAL	PHASE 1	PHASE 1B/2	PHASE 3	REGULATORY SUBMISSION	APPROVED	COMMERCIAL RIGHTS	
<b>QINLOCK</b> (ripretinib) 50mg tablets Broad-Spectrum Inhibitor of KIT and PDGFRA	GIST ≥4 <sup>th</sup> Line (INVICTUS Study)	[Progress bar]					(1)	(2) + Global Approvals <sup>(3)</sup>	
	GIST 2 <sup>nd</sup> Line (INTRIGUE Study)	[Progress bar]							
	GIST Post-Imatinib in Combination with Binimetinib	[Progress bar]							
<b>Vimseltinib (DCC-3014)</b> Selective Inhibitor of CSF1R	Tenosynovial Giant Cell Tumor (TGCT)	[Progress bar]							
<b>Rebastinib</b> Selective Inhibitor of TIE2	Multiple Solid Tumors in Combination with Paclitaxel	[Progress bar]							
<b>DCC-3116</b> Selective Inhibitor of ULK	RAS/RAF Mutant Cancers in Combination with Trametinib	[Progress bar]							
<b>Additional Programs</b>	Undisclosed	[Progress bar]							



**Notes:** CSF1R=colony-stimulating factor 1 receptor; GIST=gastrointestinal stromal tumor; KIT=KIT proto-oncogene receptor tyrosine kinase; PDGFRA=platelet-derived growth factor receptor  $\alpha$ ; RAS=rat sarcoma gene; TIE2=TEK tyrosine kinase; TGCT=tenosynovial giant cell tumor; ULK=unc-51-like kinase; (1) Submitted and received validation of a Marketing Authorisation Application for QINLOCK in 4<sup>th</sup> line GIST by the European Medicines Agency; (2) Exclusive development and commercialization license with Zai Lab in Greater China for QINLOCK; (3) QINLOCK is approved for 4<sup>th</sup> line GIST in the United States, Australia, Canada, China, and Hong Kong.